Modification of Apremilast from Pills to Aerosol a Future Concept
Background: Inhaled drugs have been available in the market for several years and for several diseases. Drugs for chronic obstructive pulmonary disease, cystic fibrosis, and diabetes have been used for several years. In the field of drug modification, these drugs range from tablets to aerosol. Metho...
Enregistré dans:
Auteurs principaux: | Paul Zarogoulidis, Christoforos Kosmidis, Nikolaos Kougkas, Aimilios Lallas, Dimitris Petridis, Wolfgang Hohenforst-Schmidt, Haidong Huang, Lutz Freitag, Chrisanthi Sardeli |
---|---|
Format: | article |
Langue: | EN |
Publié: |
MDPI AG
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/2f545a093e504e6bba8c1b6b243e6a2d |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Psoriasis In Patients With Active Lung Cancer: Is Apremilast a Safe Option?
par: Zoe Apalla, et autres
Publié: (2019) -
The Use of Apremilast in Psoriasis: An Indian Perspective on Real-World Scenarios
par: Rajagopalan M, et autres
Publié: (2021) -
Preparation of sustained release apremilast-loaded PLGA nanoparticles: in vitro characterization and in vivo pharmacokinetic study in rats
par: Anwer MK, et autres
Publié: (2019) -
Small Molecules, Big Promises: Improvement of Psoriasis Severity and Glucidic Markers with Apremilast: A Case Report
par: Lanna C, et autres
Publié: (2019) -
Outcomes of various types of therapy in patients with treatment-resistant acrodermatitis continua of Hallopeau
par: Smirnova LM, et autres
Publié: (2019)